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SHORT REPORT
Fatty acid binding protein 
deletion suppresses inflammatory pain 
through endocannabinoid/ 
N-acylethanolamine-dependent mechanisms
Martin Kaczocha1*†, Sherrye T. Glaser2†, Thomas Maher3, Brendan Clavin3, John Hamilton3, Joseph O’Rourke3, 
Mario Rebecchi1, Michelino Puopolo1, Yuji Owada4 and Panayotis K. Thanos3
Abstract 
Background: Fatty acid binding proteins (FABPs) serve as intracellular carriers that deliver endocannabinoids and 
N-acylethanolamines to their catabolic enzymes. Inhibition of FABPs reduces endocannabinoid transport and catabo-
lism in cells and FABP inhibitors produce antinociceptive and anti-inflammatory effects in mice. Potential analgesic 
effects in mice lacking FABPs, however, have not been tested.
Findings: Mice lacking FABP5 and FABP7, which exhibit highest affinities for endocannabinoids, possessed elevated 
levels of the endocannabinoid anandamide and the related N-acylethanolamines palmitoylethanolamide and oleoy-
lethanolamide. There were no compensatory changes in the expression of other FABPs or in endocannabinoid-related 
proteins in the brains of FABP5/7 knockout mice. These mice exhibited reduced nociception in the carrageenan, for-
malin, and acetic acid tests of inflammatory and visceral pain. The antinociceptive effects in FABP5/7 knockout mice 
were reversed by pretreatment with cannabinoid receptor 1, peroxisome proliferator-activated receptor alpha, and 
transient receptor potential vanilloid 1 receptor antagonists in a modality specific manner. Lastly, the knockout mice 
did not possess motor impairments.
Conclusions: This study demonstrates that mice lacking FABPs possess elevated levels of N-acylethanolamines, con-
sistent with the idea that FABPs regulate the endocannabinoid and N-acylethanolamine tone in vivo. The antinocicep-
tive effects observed in the knockout mice support a role for FABPs in regulating nociception and suggest that these 
proteins should serve as targets for the development of future analgesics.
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provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Findings
Background
Fatty acid binding proteins (FABPs) are intracellular 
lipid chaperones that are expressed in cells of the cen-
tral and peripheral nervous system [1–3]. In addition to 
fatty acids, FABPs interact with other endogenous lipids 
including the endocannabinoids, anandamide (AEA) and 
2-arachidonoylglycerol (2-AG), and related N-acylethan-
olamines (NAEs) [4–7]. Endocannabinoids activate can-
nabinoid receptor 1 (CB1) to produce antinociceptive 
effects [8, 9]. Similarly, the NAEs palmitoylethanolamide 
(PEA) and oleoylethanolamide (OEA) activate per-
oxisome proliferator-activated receptor alpha (PPARα) 
centrally and peripherally to produce analgesic and anti-
inflammatory effects [10, 11].
We have previously shown that FABP5 and FABP7 
bind to endocannabinoids/NAEs with high affinities 
[5, 12]. FABPs mediate the intracellular trafficking of 
endocannabinoids/NAEs to their catabolic enzyme(s) 
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such as fatty acid amide hydrolase (FAAH) [4]. Conse-
quently, inhibition of FABPs reduces endocannabinoid 
uptake and inactivation [4]. Recently, we have shown 
that pharmacological inhibition of FABPs elevates brain 
levels of AEA. Similarly, others have demonstrated 
that mice lacking FABP5 likewise possess elevated 
brain AEA levels [6, 13]. Pharmacological inhibition of 
FABPs produces antinociceptive effects that are medi-
ated by both CB1 and PPARα, suggesting the involve-
ment of endocannabinoids and NAEs such as PEA [6, 
14].
To date, it is not known whether mice deficient in 
FABP5 and FABP7 exhibit alterations in NAE and endo-
cannabinoid levels and/or show altered nociception. 
Herein, we characterize the endocannabinoid system in 
mice lacking both FABP5 and FABP7 and provide evi-
dence that these FABPs regulate the endocannabinoid/
NAE tone in  vivo. Furthermore, we examined nocicep-
tion in these animals and demonstrate that the antino-
ciceptive effects observed in these mice involve multiple 
receptors.
Results
Characterization of the endocannabinoid system 
in FABP5/7 KO mice
Generation of the FABP5/7 KO mice has been previ-
ously described [15]. We examined the expression of all 
ten FABP subtypes (FABP1-9 and FABP12) in the brains 
of WT and FABP5/7 KO mice. As expected, FABP3, 
FABP5, and FABP7 were expressed in WT brains and 
FABP5 and FABP7 were selectively deleted in FABP5/7 
KO mice (Fig.  1a, b). Compensatory upregulation of 
other FABP subtypes was not observed in the brains of 
FABP5/7 KO mice (Fig.  1a). Previous work has shown 
that pharmacological FABP inhibition elevates brain 
endocannabinoid levels [6]. We confirmed that levels 
of the endocannabinoid AEA were likewise elevated 
in the brains of FABP5/7 KO mice (Fig.  1c). Further-
more, levels of the NAEs PEA and OEA were likewise 
elevated. 2-AG levels seemed slightly elevated but this 
did not reach statistical significance (p  =  0.06). To 
confirm that the elevations in endocannabinoid/NAE 
levels were not due to changes in FAAH activity, AEA 
Fig. 1 Characterization of the brain endocannabinoid system in FABP5/7 KO mice. a RT-PCR analysis of FABP expression in brains of WT and 
FABP5/7 KO mice. Note that of the ten FABP isoform profiled, selective deletion of FABP5 and FABP7 was observed in the brains of FABP5/7 KO 
mice. b Western blot confirms the absence of FABP5 and FABP7 in the brains of FABP5/7 KO mice. c Brain PEA, OEA, AEA, and 2-AG levels in WT and 
FABP5/7 KO mice. *p < 0.05; **p < 0.01; ***p < 0.001 (n = 6). d Hydrolysis of AEA in brain homogenates of WT and FABP5/7 KO mice. e Representa-
tive western blots of brain FAAH, MAGL, COX-2, NAPE-PLD, and CB1 expression in WT and FABP5/7 KO mice. f Quantification of western blots 
expressed as a ratio of fold change between FABP5/7 KO and WT mice
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hydrolysis was examined in homogenates of brains 
from WT and FABP5/7 KO mice and no differences 
in AEA hydrolysis were observed between the geno-
types (Fig. 1d). Lastly, we employed western blotting to 
examine changes in expression of proteins associated 
with the endocannabinoid system in FABP5/7 KO mice. 
There were no changes in CB1 receptor levels or in the 
expression of the endocannabinoid/NAE biosynthetic 
enzyme N-acyl phosphatidylethanolamine phospholi-
pase D (NAPE-PLD) or the endocannabinoid catabolic 
enzymes FAAH, monoacylglycerol lipase (MAGL), 
and cyclooxygenase-2 (COX-2) (Fig.  1e, f ). These data 
indicate that FABP5/7 KO mice possess elevated endo-
cannabinoid/NAE levels, consistent with their role of 
gating the catabolism of endocannabinoids/NAEs by 
their respective enzyme(s).
Nociception in FABP5/7 KO mice
Baseline nociception was examined in WT and FABP5/7 
KO mice. There were no differences in tail withdrawal 
latencies between the genotypes in the tail immersion 
test (Fig. 2a). Similarly, there were no differences in base-
line thermal withdrawal latencies in the Hargreaves test 
(Fig.  2b). However, clear differences emerged in mice 
subjected to an inflammatory insult. In the carrageenan 
model of peripheral inflammation, WT mice developed 
thermal hyperalgesia and this was significantly attenuated 
in FABP5/7 KO mice (Fig.  2b). Furthermore, FABP5/7 
KO exhibited reduced paw edema following carrageenan 
challenge (Fig. 2c).
We assessed FABP5/7 KO mice in two additional 
pain models. In the formalin test, FABP5/7 KO mice 
showed reduced nociception during the first phase of 
Fig. 2 Nociception in FABP5/7 KO mice. a Tail withdrawal latencies of WT and FABP5/7 KO mice in the tail immersion test (n = 6). b Paw withdrawal 
latencies in the hargreaves test in WT (white bars) and FABP5/7 KO (blue bars) mice before and 4 h after carrageenan injection. **p < 0.01 versus 
carrageenan injected WT mice (n = 6). c Paw edema in WT and FABP5/7 KO mice after carrageenan injection (n = 6). d Nociception during the 
first (left panel 0–5 min) and second (right panel 15–60 min) phases of the formalin test. *p < 0.05 (n = 9). e Acetic acid writhing in WT and FABP5/7 
KO mice. The FABP5/7 KO mice received a subcutaneous injection of vehicle, 3 mg/kg rimonabant, or 4 mg/kg GW6471 45 min before acetic acid 
injection. *p < 0.05 versus WT mice; #p < 0.05 versus vehicle-treated FABP5/7 KO mice (n = 9–12). f Carrageenan-induced thermal hyperalgesia in 
WT and FABP5/7 KO mice treated with receptor antagonists. FABP5/7 KO mice were injected with vehicle, 3 mg/kg rimonabant, 3 mg/kg SR144528, 
4 mg/kg GW6471, or 5 mg/kg capsazepine before carrageenan administration. *p < 0.05; **p < 0.01 versus carrageenan injected WT mice. #p < 0.05; 
##p < 0.01 versus carrageenan injected FABP5/7 KO mice (n = 9–12)
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the test (Fig.  2d). In the acetic acid test, FABP5/7 KO 
mice showed an attenuated writhing response (Fig.  2e). 
The receptor(s) mediating the antinociceptive effects 
in FABP5/7 KO mice were subsequently examined. 
We focused upon CB1 and PPARα receptors because 
FABP5/7 KO mice possess elevated levels of NAEs that 
serve as ligands for both of these receptors. In the acetic 
acid writhing test, treatment of mice with the CB1 antag-
onist rimonabant or the PPARα antagonist GW6471 
completely reversed the antinociceptive phenotype found 
in FABP5/7 KO mice (Fig. 2e). The involvement of these 
receptors was also examined in the carrageenan model. 
Consistent with the acetic acid test, GW6471 reversed 
the antinociceptive phenotype of FABP5/7 KO mice 
(Fig. 2f ). Surprisingly, treatment of mice with rimonabant 
or the CB2 antagonist SR144528 alone or in combination 
did not block the analgesic effects observed in FABP5/7 
KO mice.
Previous studies have demonstrated that activation of 
transient receptor potential vanilloid 1 (TRPV1) within 
the brain produces analgesia [16, 17]. Because AEA is a 
TRPV1 agonist [18] and its levels are elevated in FABP5/7 
KO mice, we examined whether these receptors may 
likewise mediate the antinociceptive effects observed 
in FABP5/7 KO mice. Indeed, the TRPV1 antagonist 
capsazepine reduced thermal withdrawal latencies in 
FABP5/7 KO mice (Fig.  2f ). These data indicate that 
FABP inhibition results in the upregulation of endocan-
nabinoids/NAEs that produce analgesia by engaging mul-
tiple receptor systems.
The pain models employed herein measure evoked 
responses, effects that can be confounded by motor 
impairment. Consequently, we examined whether 
FABP5/7 KO mice exhibit motor deficits. In the open 
field test and rotarod tests, there were no differences 
between WT and FABP5/7 KO mice (Fig. 3a, b). We also 
profiled 24 h circadian home cage behavior and found no 
differences in home cage activity between the genotypes 
with the exception of enhanced locomotion in FABP5/7 
KO mice at one time interval (Fig. 3c). These data indi-
cate that FABP5/7 KO mice, similar to FABP inhibitor 
treated mice [6], do not possess motor deficits.
Discussion
Endocannabinoids and NAEs reduce nociception 
through engagement of central and peripheral CB1 and 
PPARα receptors [11, 19]. Endocannabinoid inactivation 
proceeds through cellular uptake followed by intracellu-
lar hydrolysis [20]. Cytoplasmic FABPs transport endo-
cannabinoids/NAEs to their catabolic enzyme(s) and 
are ideally situated to control endocannabinoid/NAE 
metabolism [4]. Consequently, therapeutic targeting of 
FABPs may serve as a novel strategy for the development 
of analgesic and anti-inflammatory drugs [6, 14].
Previous work by us and others has demonstrated that 
inhibition of FABPs reduces the cellular uptake of endo-
cannabinoids [4, 21]. Consequently, pharmacological 
FABP inhibition and genetic FABP5 ablation results in 
elevated AEA levels [6, 13]. Herein we confirm that mice 
lacking FABP5 and FABP7, the brain-expressed FABPs 
with highest affinities for endocannabinoids/NAEs show 
markedly elevated AEA levels. The relatively similar ele-
vations in AEA levels between FABP5/7 KO mice and 
FABP5 KO mice [13] suggests that the contribution of 
FABP7 towards regulating the AEA tone may be mini-
mal. This is consistent with the low expression level of 
FABP7 in the adult mouse brain [22]. In addition to AEA, 
we demonstrate for the first time that ablation of FABPs 
results in elevated PEA and OEA levels, indicating that 
FABPs are important regulators of the NAE tone in vivo.
We have recently reported that mice treated 
with FABP5 and FABP7 selective inhibitors display 
Fig. 3 Motor activity in WT and FABP5/7 KO mice. a Locomotion in the open field test in WT and FABP5/7 KO mice (n = 6). b Latency to fall in the 
rotarod test for WT and FABP5/7 KO mice (n = 8–16). c Home cage activity over a 24-h period in WT and FABP5/7 KO mice. *p < 0.05 versus WT mice 
(n = 14)
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antinociceptive effects when subjected to diverse 
pain models [6, 14]. In support of this, we demon-
strate here that mice lacking FABP5 and FABP7 pos-
sess a similar antinociceptive phenotype. Similar to 
acute pharmacological FABP inhibition, the antinoci-
ceptive effects in FABP5/7 KO mice are mediated by 
CB1 and PPARα receptors. Unexpectedly, blockade 
of CB1 receptors with rimonabant failed to reverse 
the analgesic effects in the carrageenan model, which 
contrasts to our previous results following acute phar-
macological FABP inhibition [14]. This may reflect 
possible adaptive changes in response to chronic 
endocannabinoid elevation, although the exact mech-
anism responsible for this discrepancy requires fur-
ther elucidation. Although rimonabant also engages 
TRPV1 [23], the use of identical rimonabant doses 
in our prior and current study suggest that its lack 
of efficacy is unlikely to stem from off-target effects 
at TRPV1. Furthermore, using a TRPV1 antagonist, 
we provide evidence that TRPV1 receptors likewise 
mediate the analgesic effects observed in FABP5/7 KO 
mice, consistent with an established role of supraspi-
nal TRPV1 in pain modulation [16, 17]. Although we 
hypothesize that this effect may be mediated by ele-
vated levels of the TRPV1 agonist AEA, it is likewise 
possible that other FABP-regulated TRPV1 ligands 
may mediate this effect.
Conclusions
In summary, this study provides evidence that FABP5 
and FABP7 contribute to endocannabinoid/NAE metab-
olism in vivo and establishes these proteins as important 
regulators of the NAE and endocannabinoid tone. The 
observation that FABP5/7 KO mice display inflamma-
tion-associated analgesia but unchanged baseline ther-
mal withdrawal latencies suggests that inflammation 
unmasks a role for FABP-regulated ligands in pain modu-
lation. Therefore, pharmacological agents that selectively 
disrupt FABP function may serve as novel analgesics. 
Future studies aimed at characterizing the contribution 
of peripherally and centrally expressed FABPs toward 
nociception are required to conclusively delineate the 
anatomical site(s) of FABP-mediated analgesia.
Methods
Chemicals and drugs
PEA, d4-PEA, OEA, d2-OEA, 2-AG and d5-2-AG 
were from Cayman Chemical while AEA and d4-AEA 
were from R&D systems. [14C]AEA, rimonabant and 
SR144528 were obtained from the Drug Supply Program 
at the National Institute on Drug Abuse. GW6471 was 
purchased from Sigma while capsazepine was purchased 
from Cayman Chemical.
Animals
Male C57Bl/6 mice (2–3  months old) were purchased 
from Jackson Laboratories. FABP5/7 KO mice were pre-
viously described [15]. The animals were group housed 
and had ad libitum access to food and water. The animals 
were habituated to handling in the experimental room 
for at least 1  day before each experimental session. The 
experiments were approved by the Stony Brook Uni-
versity Institutional Animal Care and Use Committee 
(#277150).
Drug administration
Receptor antagonists were injected 30 min before behav-
ioral measurements and were administered in a vol-
ume of 10 µl/g body weight. Rimonabant and SR144528 
(3  mg/kg) were dissolved in saline containing 5  % etha-
nol and 5  % cremophor-EL. GW6471 (4  mg/kg) was 
dissolved in saline containing 2 % DMSO and 5 % cremo-
phor-EL. Capsazepine (5 mg/kg) was dissolved in saline 
containing 2 % DMSO and 10 % Tween 80. The antago-
nists were administered via the intraperitoneal route with 
the exception of the acetic acid test where the drugs were 
injected subcutaneously.
Nociceptive tests
The formalin, acetic acid writhing, and carrageenan-
induced inflammatory pain models were performed 
exactly as described [6]. For the tail immersion test, mice 
were gently restrained and one cm of the tail was sub-
merged in a water bath set at 56 °C. The latency to with-
draw the tail from the water bath was measured using a 
stopwatch.
Motor tests
In the open field test, mice were placed in the open 
field chamber containing a laser beam grid (San Diego 
Instruments) and beam breaks indicative of locomotion 
were scored over a 5 min period. The rotarod test using 
a rotarod apparatus (Rotamex 0192-100  M, Columbus 
Instruments) was used to examine motor coordination by 
measuring the ability of mice to remain on a rotating rod. 
During each trial, the rotating rod accelerated a linear 
rate from a set starting rate of 4 RPM to a set ending rate 
of 40 RPM, all within a 5 min time frame. Subjects were 
observed throughout the test, and falls from the axle, 
including time and fall speed, are automatically recorded 
by the apparatus. Subjects that cling to the axle—remain-
ing stationary as they rotate with the axle—are recorded 
as a “passive rotation”. Latency to fall or commit a passive 
rotation is measured by the apparatus. Subjects whose 
latency to fall or commit a passive rotation exceeds the 
designated 5  min “passes” the given trial. Subjects who 
fail to do so “fail” the trial. Home cage circadian activity 
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was measured for each mouse for a period of 72 h. The 
first 24  h acted as a habituation period and no meas-
urements were taken. Each half-hour time point from 
the two recorded days was averaged together for each 
subject.
Lipid quantification
Endocannabinoid/NAE quantification was performed 
exactly as described [6].
Enzyme assays
AEA and 2-OG hydrolysis was performed exactly as 
described [6].
RT‑PCR
Mouse brains were homogenized and cDNA syn-
thesis commenced as previously described [5]. The 
cDNA was amplified using LongAmp Taq DNA poly-
merase (New England Biolabs) using gene specific 
primers. The following primers were used: FABP1: 
5′-TCATGAAGGCAATAGGTCTG-3′ and 5′-G 
TTCAGTCACGGACTTTATGC -3′; FABP2: 5′-GAA 
AATGGGCATTAATGTGATGA-3′ and 5′-AGAAAC 
CTCTCGGACAGCAA-3′; FABP3: 5′-CATCGAGAAGA 
ACGGGGATA-3′ and 5′-TGCCATGAGTGAGAGTC 
AGG-3′; FABP4: 5′-AGTGGCAGGCATGGCCAAG 
C-3′ and 5′-GTCACCATCTCGTTTTCTC-3′; FAB 
P5: 5′-AGGAAGATGGCTGCCATGG-3′ and 5′-TGTT 
CATGACACACTCCAC-3′; FABP6: 5′-CATGAAGCGC 
CTGGGTCT-3′ and 5′-AACTTGTCACCCACGACC 
TC-3′; FABP7: 5′-AGTGGGAAACGTGACCAAAC-3′ 
and 5′-TTTCTTTGCCATCCCACTTC-3′; FABP8: 5′-CT 
ACATGAAAGCTCTAGGTGTGG-3′ and 5′-TCTC 
CAGTGTCACGATGCTC-3′; FABP9: 5′-GTGAGAGAA 
CTGGGAGTGGAAT-3′ and 5′-AGCCATTTTT 
GGACCTGGAT-3′; FABP12: 5′-ATGAAGGAATT 
GGGAGTAGGAAG-3′ and 5′-CCTGGACTTGAACC 
AAGGAG-3′; GAPDH: 5′-CGAGACCCCACTAACATC 
AAA-3′ and 5′-CTTCCACAATGCCAAAGTTGT-3′.
Western blotting
Western blot experiments were performed as described 
[5]. Blots were probed with the following antibod-
ies: COX2 (1:1000, Abcam #Ab15191), FAAH (1:1000, 
Abcam #Ab54615), MAGL (1:400, Cayman Chemi-
cal #10212), GAPDH (1:5000, Abcam #Ab8245), CB1 
(1:1000, Abcam #Ab172970), NAPE-PLD (1:400, 
Abcam #Ab95397), FABP5 (1:1000, BioVendor R&D 
#RD181060100), or FABP7 (1:200, Abcam #Ab32423). 
The blots were developed using the Immun-star HRP 
substrate (Bio-Rad) and scanned using a C-DiGiT scan-
ner (Li-COR). Protein band intensities were quantified 
and normalized to the respective GAPDH intensities. To 
quantify changes in protein expression between WT and 
FABP5/7 KO mice, ratios of normalized protein intensi-
ties were compared between the genotypes.
Statistical analysis
Behavioral data are presented as mean  ±  SEM of at 
least six animals per group. Biochemical data are pre-
sented as mean  ±  SEM of at least three independent 
experiments performed in triplicate. Statistical signifi-
cance was determined using unpaired t-tests or one-
way ANOVA followed by Dunnett or Tukey post hoc 
analyses as appropriate. Home cage activity was ana-
lyzed by two-way ANOVA followed by Bonferroni post 
hoc test. In all cases, differences of p < 0.05 were con-
sidered significant.
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